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ABSTRACT  
This study aimed at characterising the fatty acid (FA) composition of red blood cell 
(RBC) phospholipids in children and adolescents with primary hyperlipidemia, and to 
ascertain potential association with serum lipid profile and dietary factors. At this 
purpose, 54 probands aged 6-17 years were recruited. Subjects showed a low omega-3 
index (eicosapentaenoic acid, EPA + docosahexaenoic acid, DHA<4%). Compared to 
males, females had a trend towards lower levels of total monounsaturated fatty acids 
(MUFA) and MUFA/saturated fatty acids (SFAs) ratio in RBCs. An inverse relationship 
between MUFA concentration in RBCs and serum cholesterol or HDL-C/triglycerides 
ratio was found. Omega-6 polyunsaturated fatty acids (n-6 PUFA) were positively 
associated to serum HDL-C levels, and inversely to dietary cholesterol. Fibre intake was 
positively associated with MUFA/SFA ratio. In conclusion, we provide the first 
experimental data on phospholipid FA composition of RBCs in hyperlipidemic children, 
showing sex differences and an overall low omega 3-index.  
Introduction 
Hyperlipidemias are disorders of lipoprotein metabolism characterized by an increase in 
serum total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), or 
triglycerides (TG). These disorders, both primary (monogenic and polygenic inherited 
forms) and secondary (related to other diseases) forms, are considered a major cause of 
atherosclerosis and cardiovascular disease (CVD) (Newman et al. 1986; Ahmed et al. 
1998; Groner et al. 2006; Haney et al. 2007). 
The atherosclerotic process begins early in life, thus children and adolescents affected 
by primary hyperlipidemia show a particularly high risk to develop CVD later in life 
(Durrington 2003), which is mainly secondary to chronic exposure to elevated LDL-C, 
accumulating in the intima-media of large muscular arteries (Durrington 2003; McGill et 
al. 2000). Healthy lifestyle, which includes appropriate dietary pattern in agreement with 
the expert panel guidelines for CV health and risk reduction in children and adolescents 
(Expert panel …, 2011), physical activity and weight loss in case of excessive body 
weight, is the cornerstone in the treatment of hyperlipidemia and represents an important 
target for CVD prevention (Haney et al. 2007; Catapano et al. 2011). It has been suggested 
that the lipid composition of RBC membranes can be considered as an additional risk 
factor in the progression of atherosclerosis and coronary heart disease (Lausada et al. 
2007; Tziakas et al. 2010). The fatty acid (FA) composition of red blood cells (RBCs) 
generally reflects the last three months of dietary fat intake, and it is thought to be a 
biomarker of the tissue fatty acid status (Sarkkinen et al. 1994; Kuratko et al. 2009; 
Brigandi et al. 2015).  
Since erythrocytes are incapable of de novo phospholipid synthesis, chain elongation 
or desaturation of fatty acids, the major pathway to renew the RBC phospholipids is the 
direct exchange from plasma lipoproteins to the erythrocyte (Marks et al. 1960; Farquhar 
& Ahrens 1963; Reed 1968; Hodson et al. 2008). Thus, the RBC FA composition is 
postulated to better and earlier reflect the pathology of lipid metabolism, in respect to 
lipoprotein changes in blood serum, which are affected by recent food consumption 
(Sarkkinen et al. 1994; Harris & Von Schacky 2004; Novgorodtseva et al. 2011).  
Studies conducted in adults found a correlation between altered FA composition in 
RBCs and coronary heart disease, arterial hypertension, dyslipidemia and other 
atherosclerosis-related diseases (Engelmann et al. 1992; Taylor 1994; Antoku et al. 2000; 
Lausada et al. 2007; Vayá et al. 2009; Ristic-Medic et al. 2009; Tziakas et al. 2010; 
Novgorodtseva et al. 2011; Jacobs et al. 2014). Harris & Von Schacky (2004) 
demonstrated that a low content of eicosapentaenoic (EPA) and docosahexaenoic (DHA) 
acids in the RBC membranes is strongly associated with coronary hearth diseases. The 
total levels of EPA and DHA in RBCs, defined as omega-3 index, was suggested as an 
additional biomarker of CV risk, and a predictive parameter for morbidity and mortality 
from CVD (Harris & Von Schacky 2004). Since most of this class of compounds is 
contained in cell membranes, the index has been also calculated on RBC phospholipids 
and other cell types; moreover, comparison with data obtained in plasma has been 
performed (Harris & Thomas 2010; Rice et al. 2016). 
Despite the potential impact of knowing the RBC membrane FA composition in 
patients affected by lipoprotein disorders in terms of risk prediction, studies are still 
limited and mainly performed in adults. In this regard, trials carried out in children were 
mainly aimed at characterizing the phospholipid FAs of RBCs in healthy subjects (Laryea 
et al. 1990; Jakobit et al. 2009; Cortés et al. 2012), or in patients affected by other diseases 
(Decsi et al. 2002; Vanderjagt et al. 2003; Trebbe et al. 2003; Chen et al. 2004; Bu et al. 
2006; Vaisman et al. 2008; Burrows et al. 2011; Perona et al. 2013; Brigandi et al. 2015; 
Bueno et al. 2015). Furthermore, data on gender difference in RBC composition in 
childhood and adolescence have not been adequately investigated. 
The aim of the present study is to provide data on the RBC phospholipid FA 
composition in a population of Italian children and adolescents with primary 
hyperlipidemia, receiving medical nutrition therapy at least 6 months before the 
recruitment. Since RBC phospholipid FA composition is influenced by blood lipoprotein 
profile/concentration changes and diet we also investigated the association with serum 
biomarkers and dietary parameters.  
 
Materials and methods 
Subject enrolment and study design 
Fifty-four children and adolescents with primary hyperlipidemia were recruited among 
pediatric patients cared at the Department of Health Science and Pediatrics of the 
University of Turin, after a screening for eligibility. Children and adolescents included in 
the study were 6-17 years old, affected by familial hypercholesterolemia (FH), familial 
combined hyperlipidemia (FCHL) or polygenic hypercholesterolemia (PHC). Exclusion 
criteria were: secondary dyslipidemia; obesity (body mass index (BMI) ≥ 90th percentile, 
age and sex matched); renal, endocrine and liver disorders; or chronic diseases requiring 
drug treatment (i.e. immunologic, neurologic, or oncohematologic disorders). 
Participants were not on lipid-lowering treatments (including functional foods) in the 
previous 3 months and were not smoking. Children on diet therapy were selected after 
demonstrating appropriate compliance with dietary instructions, provided by a trained 
nutritionist, in the previous 2 months. Recruited subjects and their families were trained 
by a nutritionist to adhere to a properly dietary regimen, evaluated by a weekly food diary. 
Diagnostic criteria of familial hyperlipidemia were based on accepted international 
standards (Guardamagna et al. 2011). FH was diagnosed in presence of LDL-C ≥ 95th 
percentile, parental LDL-C ≥ 190 mg/dL, tendon xanthomas and/ or cardiovascular 
disease (phenotype IIA). FCHL was diagnosed in children showing TC and/or TG >90th 
age- and sex-specific percentile, with at least one parent affected by 
hypercholesterolemia, hypertriglyceridemia, or both (IIA, IV, or IIB phenotype, 
respectively), with concomitant individual and familial lipid phenotype variability. 
Children with LDL-C levels >90th percentile and a family history of dominant inherited 
hypercholesterolemia, but not fulfilling the biochemical international diagnostic criteria 
of FH or FCHL were diagnosed with PHC.  
All subjects enrolled underwent a medical examination in the morning between 8 and 
10 a.m. on the day of recruitment. Physical parameters including height, weight and blood 
pressure were measured. Height and weight were measured to the nearest 0.1 cm and 0.1 
kg respectively (Wunder SA.BI. S.r.l. Italy), with the patients wearing hospital gowns 
and had bare feet. BMI was calculated as body weight in kilograms divided by height 
squared in meters (kg/m2). Systolic and diastolic blood pressure was measured with a 
mercury sphygmomanometer during the medical examination. Fasting blood samples 
were drawn by venipuncture for the analysis of the lipid profile and the FA composition 
of RBCs. 
Children and their parents had received dietary recommendations based on the 
cardiovascular health integrated lifestyle diet (CHILD-1) for children with identified 
dyslipidemia, as in the American Academy of Pediatrics (Expert panel …, 2011). The 
essential features were: 55% of daily energy from carbohydrate, 15% from protein, 25-
30% from total fat (saturated fat <10%, MUFA and PUFA 20% of total energy), dietary 
cholesterol <100 mg/1000 kcal and no more than 200 mg/day, and 10-25 g/day of soluble 
fibre. In order to examine correct dietary habits, parents of the enrolled children, and 
probands themselves, were asked to fill in a weekly food diary to be provided at time of 
the visit. Detailed instructions on how to collect diet records were comprehensively 
explained by a nutritionist. The nutritional evaluation of macronutrients and FA content 
of the diet registered was performed with MètaDieta® Software using the Italian Food 
Composition Tables (Carnovale & Marletta 2000). 
The study protocol complied with the principles of the Declaration of Helsinki, and 
was approved by the ethics committee of the City of Health and Science University 
Hospital of Turin (EC:CS377). The protocol and the purpose of the study were carefully 
explained to the participants and to their parents; a written informed consent was obtained 
from children’s parents before enrolment in the study.  
 
Blood sample collection and separation 
Venous blood samples of 2.5 ml were drawn into vacutainer tubes containing lithium 
heparin (to obtain plasma and RBCs) or silicon (to obtain serum). Plasma and serum were 
separated by centrifugation at 1400 g for 15 min at 4°C. Plasma was stored at -80°C for 
further analysis, while serum was immediately analysed. The buffy layer of white blood 
cells was removed using a pipette, and RBCs were washed twice in an equal volume of a 
physiologic solution (0.9% NaCl, w/v). Two aliquots (0.5 ml) of RBCs were stored at -
80°C until the analysis. 
 
Serum lipid profile 
Serum levels of TC, HDL-C and TG were directly determined by an automatic 
biochemical analyzer (Olympus AU2700, Japan), while the LDL-C concentration was 
estimated using the Friedewald formula (LDL= TC-(HDL+TG/5). Non-high density 
lipoprotein cholesterol (non–HDL-C) was calculated as TC minus HDL-C. 
Analysis of FA composition of RBC phospholipids  
Extraction of RBC phospholipids was performed in accordance to the method previously 
described by Simonetti et al. (2002). Briefly, 1 ml of distilled water, 300 mg of RBC, 2.5 
ml of butylated hydroxitoluene (110 µg/ml in methanol), and 5 ml of chloroform were 
transferred into 10 ml plastic tubes. The mixtures were shaken on vortex for 3 min and 
centrifuged at 1200 g x for 10 min. The chloroform phase was transferred into 10 ml 
plastic tubes. An aliquot of 2.5 ml chloroform was added to the tubes containing RBCs 
to perform the second extraction by vortexing for 3 min, and, after centrifugation at 1200 
g x for 10 min, the supernatant was transferred into the corresponding tube. The 
chloroform phase was eluted on a silica cartridge (Sep-Pack PlusSilica, Waters), which 
was then evaporated under nitrogen steam. The silica phase was transferred into Pyrex 
glass tubes, and 2.5 ml of a toluene/methanol (1:4 v/v) mixture and 200 µl of acetyl 
chloride were added. After 1 h in an oven at 100°C, 5 ml of K2CO3 (6% w/v in water) 
was added to the silica. After centrifugation at 1200 g x 10 min, the supernatant was 
transferred into amber glass vials, dried under nitrogen and resuspended in 100 µl of 
hexane before gas chromatography analysis. 
The gas chromatography analysis was performed as described by Ackman (1986), 
partly modified. Separations were performed with a 30 m 0.32 mm i.d. Omegawax 320 
capillary column, under these conditions: initial isotherm, 140 °C for 5 min; temperature 
gradient, 2 °C/min to 210°C; final isotherm, 210°C for 20 min. The injector temperature 
was 250°C. Injection volume was 1 µl with a split ratio of 1/100, and the flame ionization 
detector temperature was 250°C. Carrier and makeup gas were hydrogen and nitrogen, 
respectively. Fatty acid retention times were obtained by injecting the Omegawax test 
mix as standard. 
Statistical analysis 
Statistical analysis was carried out by R statistic software (version 3.1.2). One way 
repeated-measures analysis of variance (ANOVA) was used to compare the data obtained 
from subjects stratified by sex and by type of hyperlipidemia; post-hoc analysis of 
differences between paired data was assessed, when appropriate, by the Least Significant 
Difference. Differences in serum lipid concentrations, anthropometric data and the 
proportion of FA composition of RBCs in relation to different lipid disorders was 
evaluated by non-parametric Wilcoxon-Mann-Whitney test with Benjamini-Hochberg 
correction. The relationship among variables was assessed by Kendall and Spearman 
rank, non-parametric correlation tests. This approach was used to achieve the significance 
level and the trend (direct or inverse) of the data correlation. The level of statistical 
significance was set at p<0.05; data are presented as a mean and standard deviation (SD). 
 
Results 
Subjects characteristics  
The main features of the study sample are summarized in Table 1. The cohort of children 
and adolescents included 54 hyperlipidemic subjects (26 F), aged 6-17 years old; 14 were 
affected by FH (7 F), 21 by FCHL (12 F) and 19 by PHC (7 F). Five subjects were slightly 
overweight; mean blood pressure levels were in the normal range.  
 
Serum lipid profile and RBC phospholipid composition  
Serum lipid profile and RBC phospholipid composition of the patients, are reported in 
Table 2, and classified according to gender and clinical diagnosis. Mean serum lipid 
parameters exceeded the 90th percentiles (age and sex related), except for HDL-C, 
showing normal concentrations. RBC phospholipid composition was 
SFA>PUFA>MUFA, with low omega-3 index value (3.76 ± 1.04%).  
No significant serum lipid concentration difference was observed between males and 
females, while it was detected in the phospholipid composition of RBCs, as females 
showed higher concentrations of stearic acid but lower DGLA concentration (p= 0.031 
and 0.050, respectively). Moreover, MUFA content and MUFA/SFAs ratio in RBCs was 
lower in females than males (p= 0.052 and 0.056, respectively). 
A further analysis considering the type of hyperlipidemia revealed that children with 
FH had higher levels (p< 0.001) of serum TC, LDL-C and non-HDL-C, and lower serum 
HDL/LDL ratio if compared to children with FCHL or PHC. Finally, significantly lower 
levels of vaccenic acid and γ-linolenic acid were detected in FH as compared to PHC 
children (p= 0.036 and 0.027, respectively). 
 
Correlation between RBC phospholipid composition and serum lipid profile 
Correlations between serum lipid levels and RBC phospholipid composition are reported 
in Table 3. Lower RBC MUFA levels correlated with higher serum TC levels (p= 0.032) 
and HDL/TG ratio (p= 0.025), but lower serum TG levels (p= 0.005). A positive 
correlation between serum HDL-C and PUFA n-6 levels (p= 0.048) was also detected. 
 
Food diary analysis and correlation between dietary factors, RBC phospholipid 
FAs and serum lipid profile  
Complete and detailed weekly food diaries were obtained from 23 (7 F) out of 54 children, 
and were used to calculate mean daily energy and macronutrient intake. Results showed 
a mean daily total energy intake of 1208 ± 151 kcal suggesting a possible overall 
underestimation of food intake (e.g. in terms of portion size declared). Macronutrients 
distribution, expressed as percentage of daily energy intake, was: 16.7 ± 2.8% protein, 
58.6 ± 6.1% carbohydrate and 24.7 ± 6.4% fat (saturated: 7.4 ± 2.1 %, monounsaturated: 
10.3 ± 4.8 %, polyunsaturated: 2.6 ± 0.5 %). Estimated cholesterol intake was 136.2 ± 
47.2 mg/day, while fibre intake was 14.0 ± 5.3 g/day, confirming previous data 
(Guardamagna et al. 2013; Guardamagna et al. 2014). Correlations between dietary 
factors, the RBC phospholipid composition and serum lipid profile are reported in Table 
4. An inverse association was found between the dietary intake of cholesterol and n-6 
PUFA and n-6 LC-PUFA levels in RBC phospholipids (p= 0.001 and 0.017, 
respectively). The fibre intake was directly associated with RBC MUFA/SFA ratio (p= 
0.035). 
 
Discussion 
To our knowledge, this is the first study aimed at characterizing the FA composition of 
RBC phospholipids in a population of Italian children and adolescents with primary 
hyperlipidemia. 
The phospholipid composition of RBCs has been suggested as an additional marker to 
monitor serum lipoprotein profile changes (Harris et al. 2004; Novgorodtseva et al. 2001) 
and as an outcome parameter in the management of hyperlipidemia, although no reference 
values exist neither for healthy nor hyperlipidemic adults or children. Alterations of the 
erythrocyte lipid matrix have been demonstrated in studies performed in adults affected 
by dyslipidemia and/or with risk factors for coronary heart diseases (Laryea et al. 1990; 
Engelmann et al. 1992; Taylor 1994; Antoku et al. 2000; Lausada et al. 2007; Vajá et al. 
2009; Restic-Medic et al. 2009; Novgorodtseva et al. 2011; Jacobs et al. 2014). For 
instance, Novgorodtseva et al. (2011) described reduced levels of n-3 PUFA, in particular 
docosapentaenoic acid (22:5n-3) and DHA (22:6n-3), in dyslipidemic patients as 
compared to normal subjects. Lausada et al. (2007) documented a PUFA decrease and 
SFA concentrations increase in plasma and RBC membranes of patients with coronary 
heart disease, as compared to controls. 
Similar studies have been performed in children with diabetes, attention-deficit 
hyperactive disorder, autism, and other various disorders, except for hyperlipidemia, thus, 
making the comparison of our data with other data from literature extremely difficult 
(Decsi et al. 2002; Vanderjagt et al. 2003; Trebbe et al. 2003; Chen et al. 2004; Bu et al. 
2006; Vaisman et al. 2008; Burrows et al. 2011; Perona et al. 2013; Brigandi et al. 2015; 
Bueno et al. 2015). Results obtained in subjects with disorders seem to differ from those 
obtained in the relative controls. As an example, Perona et al. (2013) found higher levels 
of SFAs, and reduced concentrations of MUFAs and n-6 PUFAs in RBC membranes of 
obese adolescents as compared to normal weight controls. These results are in line with 
our observations as hyperlipidemic children and adolescents showed comparable SFA 
and MUFA levels. However, it should be also underlined that values obtained in different 
studies and different countries can be significantly affected by the dietary habits, thus 
direct comparison of results is not always possible. 
It is recognized that children affected by hyperlipidemia exhibit an increased risk of 
atherosclerosis and CVD during adulthood (McGill et al. 2000; Durrington 2003). 
Recently, the PANIC study evaluated the association between plasma FA composition 
(in triacylglycerol and phospholipid fractions), the estimated desaturase/elongase 
activities and the cardiometabolic risk in 384 children (Venäläinen et al. 2016). Authors 
found a significant positive correlation between FAs metabolism and the cardiometabolic 
risk score for the pediatric population.  
The omega-3 index may represent a novel, physiologically relevant and graded risk 
factor to predict CVD development, thus having a significant clinical utility. A low index 
(≤4%) was associated with a high risk of mortality for CVD and a value ≥8% was 
suggested as a reasonable preliminary target for reducing the risk (Harris & Von Schacky 
2004; Von Schacky 2010). In the pediatric population, only one other study examined the 
omega-3 index and concluded that a greater proportion of obese children had a lower 
index compared with non-obese children (Burrows et al. 2011). In our study, we 
documented mean omega-3 index <4% in hyperlipidemic children, a factor that 
contribute to classify them as at future high risk for CVD. Since EPA and DHA derive 
from essential fatty acids, these results suggest that there is a reduced synthesis or patients 
did not regularly consume LC-PUFA rich food sources. In this regard, the use of whole 
dietary strategies and/or specific supplementations (e.g. with PUFA, MUFA or other food 
bioactives) could be fundamental to improve this index above all in at risk subjects such 
as hyperlipidemic children. 
The present analysis on sex-related differences showed that females had a significantly 
greater proportion of the SFA stearic acid, and lower proportion of n-6 PUFA, in 
particular DGLA. Lower DGLA values were also observed in serum 
glycerophospholipids of healthy young girls when compared with boys (Glaser et al. 
2010). Moreover, in females we found a trend towards lower level of MUFA and 
MUFA/SFA ratio in RBCs with respect to males. Venäläinen et al. (2016) reported that 
a higher plasma level of SFA myristic acid, MUFA palmitoleic acid and reduced 
concentrations of n-6 PUFA (linoleic acid) have been correlated with increased 
cardiometabolic risk in children. Furthermore, higher levels of stearic, palmitic acids and 
lower levels of linoleic acid in RBC membranes were observed in obese adolescents 
(Perona et al. 2013) and in hypercholesterolemic adults (Taylor 1994), as compared to 
healthy controls. Both sex and gender differences in the pathogenesis, progression and 
manifestation of atherosclerosis and CVD have been well documented for adults (Maas 
& Appelman 2010; Mosca et al. 2011; Spence & Pilote 2015), while controversial data 
have been reported in children (Marelli et al., 2010; Krishnan et al., 2012). In this context, 
our preliminary findings on sex differences in the pediatric population, associated with 
higher risk of future coronary diseases, in terms of lipid profile and CVD risks, could be 
considered by future studies in this field. 
Children affected by FH had significantly lower levels of MUFA, vaccenic acid and 
n-6 PUFA γ-linolenic acid in RBCs, with respect to FCH or PCH patients. These data are 
consistent with earlier findings in adults demonstrating that subjects with 
hypercholesterolemia and advanced coronary heart disease exhibited a decreased PUFA 
level and an increased cholesterol and SFA concentrations in erythrocytes related to the 
atherosclerotic condition (Taylor 1994; Lausada et al. 2007; Vayá et al. 2009; 
Novgorodtseva et al. 2011). As far as the pediatric age is concerned, a significantly lower 
level of vaccenic acid in RBCs was also found in diabetic children, as compared to 
controls (Decsi et al. 2002).  
Correlation analysis performed on the whole study sample (n= 54) showed a positive 
association between the n-6 PUFA levels in RBCs and serum HDL-C concentrations, 
which was similar to other observations in young or adults, showing a direct relationship 
between serum n-6 PUFAs and HDL-C (Ferrucci et al. 2006; Motoyama et al. 2009; 
Jelenkovic et al. 2014). Furthermore, we observed an inverse correlation between MUFA 
in RBCs and serum TC concentration and HDL/TG ratio. These results are in agreement 
with those from previous clinical studies showing that diet rich in MUFA have potential 
hypocholesterolemic effect (Yu et al. 1995; Gill et al. 2003; Fernandez et al. 2005; 
Mukuddem-Peterson et al. 2005). In addition, we found a direct correlation between 
MUFA in RBCs and serum TG. These results are in line with a study conducted in two 
cohorts of young healthy twins, in which the contribution of genetic and environmental 
factors at the bases of relationship between FAs and lipoprotein profile have been 
performed. Results obtained demonstrated the importance of common genetic factors in 
determining the phenotypic covariation of n-6 PUFAs and MUFAs with TG and VLDL 
particles (Jelenkovic et al., 2014). The role of metabolic features and genetic factors on 
lipid profile is widely studied (Xiang et al. 2007; Matthan et al. 2014; Mayneris-Perxachs 
et al. 2014; Tosi et al. 2014). For example, recent evidences indicate that FA desaturases 
play an important role in defining blood and tissue lipid profiles. Polymorphisms in the 
FA desaturase genes FADS1 and FADS2, that encode respectively for the delta-5 and 
delta-6 desaturases, have been associated with PUFA levels in both serum phospholipids 
and RBC membranes (Schaeffer et al. 2006; Malerba et al. 2008; Tosi et al. 2014). Since 
diet could have also contributed, we tried to correlate dietary factors with lipid profile in 
both serum and RBCs. A correlation between low intake of dietary cholesterol and high 
level of n-6 PUFA and n-6 LC-PUFA in RBCs was found. In addition, the fibre intake 
was directly associated with the MUFA/SFA ratio. These associations have been obtained 
on a subgroup of children/adolescents involved (23 out of the 54 subjects) and this can 
represent a possible limitation of the study. However, these results provide additional 
evidence supporting that a low-cholesterol and fibre-rich diet could contribute to a more 
favourable RBC phospholipid FA composition in hyperlipidemic children.  
Finally, although a limitation of the study is the absence of a normolipidemic control 
group, our data provides for the first time information about the phospholipid composition 
of RBCs in a relatively large population of Italian hyperlipidemic children and 
adolescents. 
 
Conclusion 
In conclusion, although preliminary, we provided experimental evidence about 
differences in the phospholipid composition of RBCs according to patient type of 
hyperlipidemia and sex. The low omega-3 index, evaluated on phospholipid RBCs, 
observed in these children confirms the importance of the quality of dietary FAs intake, 
particularly in those with primary hyperlipidemia. Further studies should be performed in 
order to clarify the RBC phospholipid composition differences between hyperlipidemic 
and normolipidemic children, as well as in relation to sex and diagnosis. Moreover, it 
would be interesting to study the contribution of specific dietary interventions/regimen 
on these parameters in children affected by primary hyperlipidemia.  
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Table 1. Subject characteristics (n= 54) 
Parameter  Value 
Age, years (range) 11 ± 3 (6-17) 
Sex, M/F 28/26 
Weight, kg 47.9 ± 16.4 
Height, cm 149.1 ± 16.1 
BMI, kg/m2 20.9 ± 4.0 
Systolic blood pressure, mmHg 104.5 ± 10.1 
Diastolic blood pressure, mmHg 66.6 ± 7.4 
Notes: BMI, body mass index. Values are reported as mean ± SD. 
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Table 2. Serum lipid concentrations and RBC phospholipid FAs composition in hyperlipidemic children and adolescents (n= 54), according to sex 1 
and type of hyperlipidemia  2 
Lipid profile 
All subjects  Sex  Dyslipidemia 
  Male  Female  
p-value 
 
FH FCHL PHC 
p-value 
n= 54   n= 28 n= 26   n=14 n= 21 n= 19 
Serum lipids (mg/dl)             
TC  232.4 ± 55.6 
 226.0 ± 56.7 239.2 ± 54.8 0.385  288.2 ± 67.1a 214.2 ± 38.3b 211.4 ± 30.8b < 0.001 
TG  90.9 ± 51.9 
 94.0 ± 53.4 84.9 ± 50.3 0.658  73.6 ± 31.3 102.3 ± 67.6 91.1 ± 42.1 0.282 
HDL-C  58.8 ± 15.4 
 58.6 ± 15.6 60.2 ± 14.6 0.912  55.0 ± 10.6 57.8 ± 19.6 62.7 ± 12.7 0.340 
LDL-C  156.3 ± 58.4 
 149.1 ± 60.9 163.3 ± 56.8 0.355  219.9 ± 69.5a 137.3 ± 36.5b 130.3 ± 28.0b < 0.001 
HDL/LDL ratio 0.4 ± 0.2 
 0.4 ± 0.2 0.4 ± 0.2 0.502  0.3 ± 0.1a 0.5 ± 0.2b 0.5 ± 0.2b < 0.001 
HDL/TG ratio 0.9 ± 0.5 
 0.8 ± 0.5 0.9 ± 0.5 0.537  0.9 ± 0.5 0.8 ± 0.5 0.8 ± 0.4 0.812 
Non-HDL-C 173.6 ± 59.4 
 167.4 ± 61.7 179.0 ± 58.1 0.433  233.2 ± 71.0a 156.5 ± 42.5b 148.6 ± 31.4b < 0.001 
 
          
RBC phospholipid FAs (%)          
Total SFAs 48.99 ± 2.23 
 
48.66 ± 2.51 49.44 ± 1.84 0.261  49.23 ± 2.87 49.35 ± 1.53 48.43 ± 2.35 0.389 
Total MUFAs 18.45 ± 0.91 
 
18.68 ± 0.84 18.12 ± 0.87 0.052  18.07 ± 0.77 18.59 ± 0.86 18.58 ± 1.02 0.197 
Total PUFAs 32.55 ± 2.14 
 
32.65 ± 2.55 32.44 ± 1.67 0.729  32.70 ± 2.81 32.06 ± 1.61 32.99 ± 2.10 0.383 
MUFAs/SFAs ratio 0.38 ± 0.03 
 
0.39 ± 0.03 0.37 ± 0.03 0.056  0.37 ± 0.03 0.38 ± 0.02 0.39 ± 0.03 0.296 
PUFAs/SFAs ratio 0.67 ± 0.08 
 
0.68 ± 0.09 0.66 ± 0.06 0.452  0.67 ± 0.11 0.65 ± 0.05 0.68 ± 0.08 0.391 
PUFAs n-3/n-6 0.19 ± 0.06 
 0.18 ± 0.03 0.20 ± 0.05 0.758  0.19 ± 0.05 0.20 ± 0.07 0.19 ± 0.04 0.871 
LC-PUFAs n-3/n-6 0.33 ± 0.09 
 0.31 ± 0.05 0.34 ± 0.09 0.633  0.33 ± 0.09 0.34 ± 0.11 0.32 ± 0.08 0.822 
Omega-3 index  3.76 ± 1.04 
 3.54 ± 0.55 3.80 ± 1.08 0.770  3.81 ± 0.87 3.84 ± 1.24 3.62 ± 0.95 0.789 
 
  
 
 
  
 
 
 
 
Saturated 
  
 
 
  
 
 
 
 
14:0 (myristic acid) 0.41 ± 0.08 
 0.40 ± 0.09 0.42 ± 0.08 0.336  0.42 ± 0.10 0.4 ± 0.07 0.4 ± 0.08 0.789 
15:0 (pentadecanoic acid) 0.16 ± 0.03 
 0.16 ± 0.03 0.17 ± 0.03 0.152  0.16 ± 0.03 0.16 ± 0.02 0.16 ± 0.03 0.963 
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16:0 (palmitic acid) 24.05 ± 1.38 
 24.02 ± 1.52 24.08 ± 1.23 0.864  24.4 ± 1.56 24.06 ± 1.10 23.78 ± 1.52 0.625 
17:0 (margaric acid) 0.46 ± 0.17 
 0.46 ± 0.16 0.45 ± 0.19 0.803  0.42 ± 0.22 0.44 ± 0.19 0.51 ± 0.11 0.387 
18:0 (stearic acid) 15.47 ± 1.47 
 15.06 ± 1.40a 15.92 ± 1.44b 0.031  
15.61 ± 2.10 15.68 ± 1.16 15.15 ±  1.24 0.593 
20:0 (arachidic acid) 0.56 ± 0.15 
 0.58 ± 0.20 0.55 ± 0.05 0.579  0.54 ± 0.07 0.55 ± 0.05 0.6 ±  0.23 0.610 
22:0 (behenic acid) 1.99 ± 0.28 
 1.98 ± 1.29 1.99 ± 1.27 0.988  1.94 ±  0.32 2.02 ±  0.24 1.98 ± 0.29 0.607 
23:0 (tricosanoic acid) 0.31 ± 0.06 
 0.31 ± 0.05 0.31 ± 0.06 0.935  0.30 ± 0.07 0.32 ± 0.05 0.31 ± 0.05 0.576 
24:0 (lignoceric acid) 5.59 ± 0.75 
 5.7 ± 0.84 5.46 ± 0.63 0.242  5.45 ± 0.83 5.73 ± 0.63 5.54 ± 0.81 0.583 
 
    
  
 
 
 
 
Monounsaturated 
    
  
 
 
 
 
16:1n-9 (hypogeic acid) 0.11 ± 0.03 
 0.11 ± 0.01 0.11 ± 0.04 0.524  0.11 ± 0.04 0.11 ± 0.03 0.11 ± 0.01 0.934 
16:1n-7 (palmitoleic acid) 0.24 ± 0.07 
 0.24 ± 0.07 0.23 ± 0.07 0.561  0.23 ± 0.08 0.23 ± 0.08 0.25 ± 0.05 0.795 
18:1n-9 (oleic acid) 11.09 ± 0.94 
 11.16 ± 0.89 11.02 ±  1.01 0.569  11.19 ± 1.16 10.95 ± 0.91 11.18 ± 0.83 0.719 
18:1n-7 (vaccenic acid) 1.08 ± 0.11 
 1.07 ± 0.10 1.09 ± 0.12 0.392  
1.02 ± 0.07a 1.08 ± 0.11ab 1.12 ± 0.10
b 0.036 
20:1n-9 (eicosenoic acid) 0.20 ± 0.08 
 0.21 ± 0.10 0.19 ± 0.02 0.474  0.18 ± 0.02 0.19 ± 0.02 0.22 ± 0.12 0.361 
24:1n-9 (nervonic acid) 5.73 ± 0.92 
 5.9 ± 1.14 5.56 ±  0.56 0.179  5.34 ± 1.11 6.02 ± 0.60 5.70  ± 0.99 0.240 
 
    
  
 
 
 
 
n-6 Polyunsaturated 
    
  
 
 
 
 
18:2n-6 (linoleic acid) 10.70 ± 1.08 
 10.72 ± 1.06 10.68 ± 1.13 0.916  10.49 ± 0.77 10.78 ± 1.13 10.78 ± 1.24 0.795 
18:3n-6 (-linolenic acid) 0.06 ± 0.02 
 0.06 ± 0.02 0.06 ± 0.02 0.193  
0.06 ± 0.02a 0.06 ± 0.02a 0.07 ± 0.02
b 0.027 
20:2n-6 (eicosadienoic acid) 0.23 ± 0.07 
 0.24 ± 0.09 0.22 ± 0.05 0.222  0.20 ± 0.06   0.23 ± 0.03 0.26 ± 0.10 0.138 
20:3n-6 (dihomo-γ-linolenic acid) 1.91 ± 0.38 
 2.01 ± 0.46a 1.81 ± 0.24b 0.050  
1.75 ± 0.26 1.95 ± 0.37 1.99 ± 0.44 0.137 
20:4n-6 (arachidonic acid) 11.05 ± 1.14 
 10.89 ± 1.29 11.23 ± 0.95 0.270  11.43 ± 1.23 10.84 ± 0.86 11.01 ± 1.33 0.446 
22:4n-6 (adrenic acid) 1.93 ± 0.49 
 1.92 ± 0.53 1.94 ± 0.44 0.867  1.9 ± 0.53 1.76 ± 0.27 2.14 ± 0.58 0.114 
Total PUFA n-6 25.89 ± 1.58 
 
26.15 ± 1.37 25.85 ± 1.50 0.815  25.83 ± 1.69 25.62 ± 1.58 26.25 ± 1.51 0.457 
Total LC-PUFAs n-6 14.90 ± 1.46 
 
15.07 ± 1.19 14.82 ± 1.64 0.681  15.08 ± 1.65 14.56 ± 1.16 15.14 ± 1.59 0.392 
 
    
  
 
 
 
 
n-3 Polyunsaturated 
    
  
 
 
 
 
18:3n-3 (α-linolenic acid) 0.09 ± 0.04  0.09 ± 0.02 0.09 ± 0.02 0.827  0.09 ± 0.04 0.09 ± 0.04 0.10 ± 0.03 0.291 
20:5n-3 (eicosapentaenoic acid) 0.36 ± 0.21 
 0.38 ± 0.21 0.33 ± 0.22 0.402  0.37 ± 0.29 0.35 ± 0.22 0.36 ± 0.12 0.988 
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22:5n-3 (docosapentaenoic acid) 1.10 ± 0.20 
 1.13 ± 0.21 1.07 ± 0.17 0.207  1.08 ± 0.20 1.04 ± 0.19 1.18 ± 0.19 0.130 
22:6n-3 (docosahexaenoic acid) 3.40 ± 0.89 
 3.41 ± 0.96 3.38 ± 0.82 0.888  3.43 ± 0.67 3.49 ± 1.05 3.26 ± 0.86 0.781 
Total PUFAs n-3 4.95 ± 1.17 
 4.68 ± 0.63 5.02 ± 1.21 0.632  4.98 ± 0.99 4.97 ± 1.39 4.90 ± 1.06 0.976 
Total LC-PUFAs n-3 4.86 ± 1.17   4.59 ± 0.63 4.93 ± 1.21 0.637   4.89 ± 0.99 4.88 ± 1.39 4.80 ± 1.06 0.970 
Notes: FH, familiar hypercholesterolemia; FCHL, familiar combined hyperlipidemia; PHC, polygenic hypercholesterolemia; TC, total cholesterol; 3 
TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; SFAs, saturated fatty acids; MUFAs, 4 
monounsaturated fatty acids; PUFAs, polyunsaturated fatty acids; LC-PUFAs, long chain polyunsaturated fatty acids (C ≥20, double bonds ≥ 3); 5 
omega-3 index, sum of EPA + DHA. Values are reported as mean ± SD. a,b Data with different letters are significantly different (p<0.05). 6 
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Table 3. Correlation between RBC phospholipid FAs and serum lipid concentrations (n= 54)  8 
RBC phospholipid fatty acids 
Serum Lipids 
TC HDL-C LDL-C TG HDL/LDL HDL/TG 
Total SFAs 0.095 -0.001 0.095 -0.077 -0.051 0.022 
Total MUFAs -0.290* -0.138 -0.274 0.371* 0.064 -0.308* 
Total PUFAs 0.020 0.072 0.021 -0.137 0.030 0.161 
MUFAs/SFAs ratio -0.208 -0.057 -0.210 0.262 0.073 -0.180 
PUFAs/SFAs ratio -0.025 0.029 -0.015 -0.058 0.021 0.084 
Total PUFAs n-3 0.104 -0.155 0.151 -0.068 -0.200 0.011 
Total PUFAs n-6 0.023 0.275* -0.028 -0.155 0.198 0.250 
PUFAs n-3/n-6 0.085 -0.220 0.151 -0.039 -0.231 -0.043 
Total LC-PUFAs n-3 0.105 -0.168 0.159 -0.064 -0.213 0.000 
Total LC-PUFAs n-6 0.174 0.207 0.120 -0.197 0.063 0.243 
LC-PUFAs n-3/n-6 -0.020 -0.229 0.059 0.006 -0.181 -0.080 
Omega-3 index 0.085 -0.203 0.160 -0.080 -0.233 -0.006 
Notes: TC, total cholesterol; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; SFAs, 9 
saturated fatty acids; MUFAs monounsaturated fatty acids; PUFAs, polyunsaturated fatty acids; LC-PUFAs, long chain polyunsaturated fatty acids; 10 
omega-3 index, sum of EPA + DHA. *Statistical significance after Kendall and Spearman correlations for multiple comparisons (p<0.05). 11 
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Table 4. Correlation between dietary factors, RBC phospholipid FAs and serum lipids (n= 23)  13 
  Dietary factors 
 Energy Protein Carbohydrate Total Fat SFAs MUFAs PUFAs PUFAs n-3  PUFAs n-6  Cholesterol Fiber 
Serum lipids                       
TC -0.265 -0.202 0.302 -0.204 -0.196 -0.221 -0.376 0.011 -0.083 -0.386 -0.210 
HDL-C -0.381 -0.126 0.163 -0.149 0.118 -0.102 -0.034 -0.087 -0.182 -0.254 -0.203 
TG -0.013 -0.101 -0.210 0.249 0.402 0.123 0.181 -0.007 0.099 0.180 0.104 
LDL-C -0.219 -0.243 0.187 -0.079 -0.147 -0.118 -0.339 0.204 -0.027 -0.280 -0.214 
HDL/LDL ratio -0.252 0.012 -0.012 -0.049 0.167 0.017 0.147 -0.081 -0.113 -0.061 -0.074 
HDL/TG ratio -0.289 -0.054 0.282 -0.289 -0.194 -0.147 -0.154 -0.010 -0.145 -0.277 -0.196 
 
           
RBC phospholipid FAs            
Total SFAs -0.145 -0.108 0.150 -0.096 -0.297 -0.105 -0.010 -0.350 0.083 0.265 -0.235 
Total MUFAs 0.103 -0.137 -0.142 0.123 0.547 0.292 0.409 0.265 0.282 0.360 0.493 
Total PUFAs -0.059 0.174 -0.044 0.049 0.081 -0.047 -0.203 0.277 -0.216 -0.485 -0.012 
MUFAs/SFAs ratio 0.193 -0.056 -0.150 0.123 0.504 0.271 0.324 0.340 0.212 0.088 0.525* 
PUFAs/SFAs ratio 0.072 0.146 -0.093 0.069 0.164 0.027 -0.108 0.321 -0.128 -0.407 0.131 
Total PUFAs n-3 0.360 0.434 -0.397 0.181 -0.039 0.027 0.017 0.105 0.039 0.137 0.135 
Total PUFAs n-6 -0.164 -0.105 0.115 0.029 -0.076 -0.054 -0.282 0.201 -0.243 -0.762* -0.245 
PUFAs n-3/n-6 0.363 0.429 -0.409 0.167 -0.059 0.010 0.029 0.078 0.049 0.260 0.150 
Total LC-PUFAs n-3 0.360 0.434 -0.397 0.181 -0.039 0.027 0.017 0.105 0.039 0.137 0.135 
Total LC-PUFAs n-6 0.002 0.071 -0.201 0.118 0.108 0.051 -0.108 0.225 -0.157 -0.522* -0.142 
LC-PUFAs n-3/n-6 0.368 0.463 -0.390 0.135 -0.083 -0.034 0.007 0.020 0.034 0.390 0.176 
Omega-3 index 0.358 0.441 -0.350 0.127 -0.076 -0.032 -0.010 0.081 0.029 0.265 0.154 
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Notes: TC, total cholesterol; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; SFAs, 14 
saturated fatty acids; MUFAs monounsaturated fatty acids; PUFAs, polyunsaturated fatty acids; LC-PUFAs, long chain polyunsaturated fatty acids; 15 
omega-3 index, sum of EPA + DHA. *Statistical significance after Kendall and Spearman correlations for multiple comparisons (p<0.05). 16 
 17 
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